Key PointsQuestionWhat factors are associated with the development of conjunctivitis in patients treated with dupilumab for atopic dermatitis? FindingsIn this case series of 12 adults in whom conjunctivitis developed during dupilumab treatment for atopic dermatitis, 9 had severe atopic dermatitis at baseline. Severe conjunctivitis was seen only in patients with severe atopic dermatitis at baseline and in those with another atopic condition in addition to atopic dermatitis. MeaningBaseline atopic dermatitis severity and history of atopic conditions should be considered when stratifying the risk for conjunctivitis development secondary to dupilumab administration for patients with atopic dermatitis.
JAMA Dermatology – American Medical Association
Published: Oct 29, 2018